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INTRODUCTION
Neural stem cells (NSCs) maintain multipotency and are ca-
pable of self-renewal;1 and it has been demonstrated that di-
viding NSCs in the subventricular and subgranular zone2 can 
become neurons.3 NSCs have been studied extensively as 
promising novel treatments for central nervous system (CNS) 
disorders.4 Several studies have demonstrated that prolifera-
tion of endogenous NSCs is enhanced after brain injury, as is 
migration of neural progenitor cells to the brain lesion.5 In ad-
dition, NSCs migrate toward injured brain regions, differenti-
ate into neurons, and then facilitate injury healing.6 Thus, NSC 
self-renewal and proliferation are important characteristics 
for the enhanced therapeutic efficiency of NSCs in the brain.7
Agmatine is an endogenous amine produced by decarbox-
ylation of L-arginine by arginine decarboxylase present in glia 
and neurons,8 and it has been reported to affect various cellu-
lar processes, such as antioxidative pathways,9 and also has a 
role in CNS injuries including neurotrauma and animal mod-
els of ischemia.10,11 Moreover, agmatine initiates early neuro-
genesis and cell proliferation.12
MicroRNAs can regulate target mRNAs via translational in-
hibition or mRNA degradation.13 Recent studies have focused 
on the mechanisms of microRNA action on NSCs, in order to 
discover potential treatments for CNS diseases.14 MicroRNA 
let-7 (let-7) is a family of microRNAs present in multiple ge-
nomic locations,15 and consists of 9 members.16 let-7 targets 
cyclin D1, and its overexpression promotes cell cycle exit and 
differentiation.17 Furthermore, let-7 suppresses differentiation 
of human embryonic stem cell derived neural progenitor cells,18 
and influences self-renewal of NSCs.19 Recent studies have sug-
gested a function of let-7 in cell fate mechanisms in neurons.20,21 
In addition, overexpression of let-7a, one of the members of 
let-7 family, influences NSC proliferation and differentiation.22,23 
However, the mechanisms of action of the let-7 family on NSC 
proliferation or neuronal differentiation are poorly under-
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stood and are debatable. Agmatine has been shown to block 
neuronal nitric oxide synthase,10,24 inducible nitric oxide syn-
thase25 and N-methyl-D-aspartate receptor channels.26 Fur-
thermore, the nitric oxide synthase inhibitor asymmetric di-
methylarginine increased the levels of microRNAs such as mi-
croRNA-21.27 Taken together, therefore, it is quite possible that 
there exists a relationship between agmatine and let-7a in the 
regulation of NSC differentiation. Accordingly, the aim of the 
present study was to investigate the effects of agmatine on 
NSCs by controlling let-7a levels. 
MATERIALS AND METHODS
NSC primary culture
Cortical NSCs were obtained from pregnant imprinting con-
trol region mice (E13.5). The cortices were dissected and 
washed 1–2 times with Hank’s Balanced Salt Solution (HBSS; 
HyClone Laboratories, South Logan, UT, USA). To each piece 
of washed tissue, 5 mL of HBSS were added, and the tissue was 
dissociated by pipetting up and down. Tissues were triturated 
by repeated passages through a fire-polished constricted Pas-
teur pipette. Dissociated tissues were allowed to settle for 3 
min. Supernatants were transferred to a fresh tube, and were 
centrifuged at 1200 g for 3 min. Pellets were resuspended in 
NSC basal media with a proliferation supplement (Stem Cell 
Technologies, Vancouver, Canada), and 20 ng/mL epidermal 
growth factor (EGF, Invitrogen, Carlsbad, CA, USA). NSCs were 
plated on poly-D-ornithine (Sigma-Aldrich, St. Louis, MO, 
USA) treated dishes at a density of 2.5×104 cells/mL. Cultures 
were maintained in a humidified atmosphere of 95% air and 
5% CO2 at 37°C. Culture medium was replaced every 3 days. 
NSCs were used for experiments after 2–3 passages.
let-7a and siRNA TLX experiment 
let-7a mimics, inhibitors, and siTLX were purchased from Am-
bion (Austin, TX, USA); they were mmu-let-7a-5p (let-7a 
mimic) (cat. #4464066) and let-7a inhibitor (cat. #4464066; as-
say ID MH10050). For RNA duplex transfection, 20 nM solu-
tions in Opti-MEM (Sigma, St. Louis, MO, USA) were combined 
with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). After 
15 min, the mixtures were added to the cells incubated for 72 h. 
Measurement of neurosphere size
Images of neurosphere cultures were taken using an inverted 
microscope (Olympus microscopy BH3, Tokyo, Japan). The 
magnification (10×) ensured coverage of a significant area of 
each well of the 24-well plates. Image analysis software (Image 
J) was used to evaluate the size of neurospheres. 
Reverse-transcription PCR 
To examine the expression of TLX, DCX, and c-Myc in NSCs, 
RT-PCR was performed using specific primers. Briefly, the cell 
pellets were lysed with TRIzol reagent (Invitrogen, Carlsbad, 
CA, USA). PCR was conducted by the following manual’s con-
ditions, and the following primers (5' to 3'): TLX, forward (F): 
GGC TCT CTA CTT CCG TGG ACA, reverse (R): GTC AGT 
ATT CAT GCC AGA TAC AGC CAG TG; DCX, (F): AAT CCC 
AAC TGG TCT GTC AAC, (R): GTT TCC CTT CAT GAC TCG 
GCA; c-Myc, (F): TCA AGA GGC GAA CAC ACA AC, (R): GGC 
CTT TTC ATT GTT TTC CA, and GAPDH, (F): ACA GTC CAT 
GCC ATC ACT GCC, (R): GCC TGC TTC ACC ACC TTC TTG. 
GAPDH was used as an internal control.
Real-time quantitative-PCR (SYBR and TaqMan assays) 
For quantitative analysis of let-7a, reverse transcription was 
first performed using the TaqMan Micro RNA Reverse Tran-
scription Kit (Takara, Otsu, Shiga, Japan) with total RNA sam-
ples of 10 ng. PCR was then performed according to the man-
ufacturer’s instructions using the TaqMan Universal PCR 
Master Mix, No Amp Erase UNG (Applied Biosystems, Foster 
City, CA, USA); PCR amplification was carried out in an ABI 
7500 Real-Time PCR cycler (Bio-Rad, Philadelphia, PA, USA). 
We used the following primers (5' to 3'): let-7a, (F): GCG CCT 
GAG GTA GTA GGT TG, (R): CAG TGC AGG GTC CGA GGT; 
and U6, (F): CTC GCT TCG GCA GCA CAT ATA CT, (R): ACG 
CTT CAC GAA TTT GCG TGT C. The let-7a levels were nor-
malized to the internal control U6. 
Western blotting 
The NSCs were homogenized in lysis buffer and centrifuged 
(12000 g at 4°C) for 15 min. Equal amounts of protein (30 µg) 
from the supernatants were separated on a 10% acrylamide gel, 
and the proteins were electrotransferred onto nitrocellulose 
membranes. After blocking, the membranes were incubated 
with primary antibody at 4°C. The primary antibodies includ-
ed anti-DCX (1:2000, Millipore, Billerica, MA, USA), anti-NeuN 
(1:1000, Santa Cruz Biotechnology, Santa Cruz, CA, USA), and 
anti-β-actin (1:2000, Santa Cruz Biotechnology) antibodies. The 
membranes were then incubated with secondary antibodies. 
The blots were rinsed, and protein bands were visualized using 
an enhanced chemiluminescence detection system (Amersh-
am, Pittsburgh, PA, USA).
Immunocytochemical analysis
The NSCs were incubated with primary antibody overnight at 
4°C (goat anti-DCX; 1:200; Millipore). Cell samples were then 
incubated with a rhodamine-conjugated donkey anti-goat an-
tibody (1:200, Jackson ImmunoResearch, West Grove, PA, USA) 
for 2 h at room temperature (RT). The NSCs were washed 3 
times again, for 3 min each with PBS. The cells were then coun-
terstained with 1 μg/mL 4', 6-diamidino-2-phenylindole (DAPI; 
1:100; Invitrogen, Carlsbad, CA, USA) for 10 min at RT and were 
photographed using a confocal microscope (Carl Zeiss, Thorn-
wood, NY, USA).
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Statistical analysis
All calculations were conducted using SPSS 18.0 software (IBM 
Corp., Armonk, NY, USA). Data are expressed as mean±SEM. 
Significance of intergroup differences was determined by 
one-way analysis of variance followed by Bonferroni post hoc 
multiple-comparison tests. Each experiment included at least 
three repeats per condition. Differences with a p value less than 
0.05 were considered statistically significant.
 
RESULTS
Alterations of NeuN and DCX expression in NSCs after 
agmatine treatment
We conducted western blot analyses of the expression of neuro-
nal markers (NeuN28 and DCX29) in NSCs after agmatine treat-
ment (Fig. 1). Treatment with agmatine (100, 200 µM) increased 
expression of NeuN (Fig. 1A) and DCX (Fig. 1B), while 50 µM ag-
matine treatment showed a small decrease of DCX protein level 
(Fig. 1B). Specifically, 100 µM agmatine treatment visibly in-
creased the protein levels of NeuN (Fig. 1A) and DCX (Fig. 1B). 
On the basis of these findings, we chose 100 µM agmatine for 
the following experiments with an assumption that 100 µM ag-
matine would promote neuronal differentiation in NSCs. 
let-7a levels in NSCs after agmatine treatment
In NSCs, we confirmed let-7a expression by a TaqMan assay 
(Fig. 2). Agmatine treatment decreased let-7a expression in 
NSCs compared with the normal control group. Although a few 
differences were observed between agmatine treatment and 
Fig. 1. Alterations in NeuN and DCX protein levels in NSCs by agmatine treatment. (A) The protein levels of NeuN increased in the agmatine treatment 
group. In particular, the 100 µM agmatine treatment significantly increased NeuN protein levels in NSCs. (B) DCX protein levels increased in the agmatine 
treatment group. Similar to NeuN, 100 µM agmatine significantly increased DCX protein levels in NSCs. β-actin was used as an internal control. Data are 
expressed as mean±SEM. *p<0.05, †p<0.001 compared to agmatine 0 uM group. Agm, agmatine treatment; NSCs, neural stem cells.
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Fig. 2. Effects of alterations of let-7a levels in neural stem cells. A TaqMan 
assay was performed to check let-7a level. The level of let-7a decreased 
in the agmatine group compared with the let-7a mimic group. U6 was 
used as an internal control. Data are expressed as mean±SEM. *p<0.05, 
†p<0.001 compared to normal control group. let-7a mimic, let-7a mimic 
treatment/let-7a overexpression group; let-7a inhibitor, let-7a inhibitor 
treatment/let-7a suppression group; Agm, 100 µM agmatine treatment 
group; Veh, Lipofectamine treatment group.
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agmatine treatment along with let-7a overexpression (the 
same with let-7a mimic treatment), we found that agmatine 
dramatically reduced let-7a levels in spite of let-7a mimic 
treatment (Fig. 2), indicating that agmatine negatively regu-
lates let-7a expression in NSCs.
Changes in DCX expression in NSCs after agmatine 
treatment during let-7a overexpression
Immunochemical images of DCX indicated that let-7a overex-
pression inhibited the expression of DCX (Fig. 3A). Agmatine 
treatment increased the number of DCX-positive cells in both 
the let-7a overexpression state (let-7a mimic treatment) and 
the normal state (Fig. 3A). Fig. 3B demonstrates that let-7a 
overexpression (let-7a mimic treatment) in NSCs decreased 
DCX mRNA levels compared with the normal control group 
(Fig. 3B). Agmatine treatment group shows DCX mRNA induc-
tion that occurred with let-7a overexpression (Fig. 3B). Our re-
sults suggest that DCX, a marker for immature neurons, was 
downregulated under let-7a overexpression, whereas DCX 
expression was increased under let-7a overexpression in ag-
matine treatment group (Fig. 3).
Relationship between TLX expression and let-7a 
levels in NSCs 
TLX mRNA levels are associated with self-renewal and prolif-
eration30 of NSCs. We found that let-7a overexpression (let-7a 
mimic treatment) increased TLX expression (Fig. 3C). Although 
the expression of TLX was increased by agmatine in NSCs, it 
Fig. 3. The expression of DCX and TLX mRNA levels in neural stem cells. (A) Immunochemical images indicated that DCX-positive cells decreased in the 
let-7a mimic group. Scale bar: 200 µm. NC: the normal control group, 4', 6-diamidino-2-phenylindole (DAPI): blue, DCX: red. (B) Under agmatine treatment, 
the let-7a suppression group (let-7a inhibitor group) expressed lower DCX mRNA levels. GAPDH was used as an internal control. (C) The let-7a mimic 
group with agmatine had decreased TLX mRNA expression compared to the let-7a mimic group. GAPDH was used as an internal control. (D) Inhibition of 
TLX expression by agmatine decreased let-7a levels. U6 was used as an internal control. Data are expressed as mean±SEM. *p<0.05, †p<0.001 compared 
to normal control group, ‡p<0.001 compared to let-7a mimic group. let-7a mimic, let-7a mimic treatment/let-7a overexpression group; let-7a inhibitor, let-7a 
inhibitor treatment/let-7a suppression group; Normal, normal control group/no treatment; Agm, 100 µM agmatine treatment group; siTLX, TLX silencing 
group; siTLX+Agm, TLX silencing with agmatine treatment group.
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was noticeably reduced in agmatine treatment group under 
let-7a mimic treatment in comparison with the let-7a overex-
pression group (Fig. 3C). In addition, we observed a slight in-
crease in TLX mRNA expression after the let-7a inhibitor treat-
ment, in comparison with the let-7a overexpression group 
under agmatine treatment conditions (Fig. 3C). In the TLX 
knockdown group, let-7a expression increased slightly, whereas 
the agmatine co-treatment group showed a marked decrease 
in let-7a expression (Fig. 3D). 
Change of c-Myc expression in NSCs 
Expression of c-Myc mRNA in NSCs was measured using real-
time quantitative RT-PCR (Fig. 4A), since c-Myc plays a crucial 
role in proliferation and self-renewal31 of NSCs. We observed 
increased expression of c-Myc in the let-7a overexpression 
group (let-7a mimic treatment) (Fig. 4A). After agmatine treat-
ment, c-Myc mRNA expression was slightly increased. How-
ever, the let-7a overexpression with agmatine treatment re-
duced the expression of c-Myc (Fig. 4A). 
Change of the ERK pathway of NSCs 
In order to determine signaling pathway affected by agmatine 
and let-7a, we measured ERK phosphorylation which is relat-
ed to NSC proliferation (Fig. 4B).12 Activation of ERK, as indi-
cated by the level of phosphorylated ERK protein, was re-
duced in NSCs after let-7a mimic treatment. Agmatine increased 
the activation of ERK in NSCs, whereas the expression of ERK 
was decreased by let-7a overexpression (Fig. 4B). Given the 
fact that ERK activation is important for proliferation and self-
renewal of NSCs,32 our results indicated that agmatine may re-
verse the decrease of ERK phosphorylation, induced by let-7a.
 
DISCUSSION
Understanding of NSC proliferation, self-renewal, and differ-
entiation is necessary to enhance the therapeutic efficacy of 
NSCs.33 Agmatine has multiple roles in several biological pro-
cesses.34,35 In the present study, we found several lines of evi-
dence indicating that agmatine can enhance NSC differentia-
tion into neurons by modulating expression of let-7a. 100 µM 
agmatine was found to promote differentiation by upregula-
tion of NeuN28 and DCX.29 Since let-7a was reduced in NSCs 
when treated with agmatine, our results suggest that agmatine 
may negatively regulate let-7a in NSCs. DCX is regarded as a 
marker of neurogenesis,36 the findings therefore suggest that 
agmatine promotes NSC differentiation into neurons: it is 
quite possible that agmatine may boost neuronal differentia-
tion by inhibiting let-7a expression.
Previous studies have demonstrated that underexpression of 
let-7a attenuates the proliferation and self-renewal of NSCs.18 
TLX is necessary for maintaining the proliferative potential of 
NSCs and neurogenesis.37 In the present study, we suggest 
that agmatine may enhance neurogenesis by negatively regu-
Fig. 4. Assessment of c-Myc mRNA and ERK phosphorylation in neural stem cells. (A) c-Myc mRNA expression was reduced in the let-7a mimic treat-
ment with agmatine group in comparison with let-7a mimic group. β-actin was used as an internal control. (B) ERK phosphorylation significantly in-
creased in the let-7a mimic treatment with agmatine group compared to let-7a mimic group. GAPDH was used as an internal control. Data are expressed 
as mean±SEM. *p<0.05, †p<0.001 compared to normal control group, ‡p<0.05 compared to let-7a mimic group. let-7a mimic, let-7a mimic treatment/let-7a 
overexpression group; let-7a inhibitor, let-7a inhibitor treatment/let-7a suppression group; Agm, 100 µM agmatine treatment group; Veh, Lipofectamine 
treatment group; p-ERK, ERK phosphorylation.
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lating expression of let-7a and TLX, and it may inhibit NSC pro-
liferation by attenuating the increased TLX level in let-7a 
overexpression conditions.38
c-Myc regulates the genes involved in self-renewal, and 
proliferation39 of NSCs, and the let-7 family is known to regulate 
cell proliferation by targeting c-Myc.40 In our present study, 
overexpression of let-7a upregulated the expression of c-Myc, 
which is known to sustain the stemness of stem cells targeted 
by the let-7 family.41 These findings imply that agmatine may 
reduce c-Myc via controlling let-7a, thereby influencing self-
renewal and proliferation of NSCs. 
It has been demonstrated that agmatine regulates neuropro-
tection and increases neuronal differentiation in NSCs by ac-
tivating ERK1/2.12 In our present study, we demonstrated that 
let-7a overexpression in NSCs decreases ERK phosphoryla-
tion, thus indicating that agmatine promotes ERK activation 
by negatively regulating let-7a, which is involved in neuronal 
differentiation and cell survival of NSCs. 
In conclusion, we found four main findings in the present 
study. 1) Agmatine increased the expression of DCX and NeuN 
in NSCs. 2) Agmatine decreased the expression of let-7a in 
NSCs. 3) Agmatine attenuated the let-7a-induced upregula-
tion of TLX and c-Myc. 4) Agmatine ameliorated the let-7a-in-
duced ERK inactivation in NSCs. Therefore, we suggest that 
agmatine manipulates the mechanism linking let-7a, and in-
duce neuronal differentiation for treatment of CNS disorders.
ACKNOWLEDGEMENTS
This research was supported by the Basic Science Research Pro-
gram through the National Research Foundation of Korea (NRF) 
funded by the Ministry of Education, Science, and Technology 
(NRF-2014R1A2A2A01006556).
REFERENCES
1. Yao J, Mu Y, Gage FH. Neural stem cells: mechanisms and model-
ing. Protein Cell 2012;3:251-61.
2. Ming GL, Song H. Adult neurogenesis in the mammalian brain: 
significant answers and significant questions. Neuron 2011;70:687-
702. 
3. Kazanis I, Lathia J, Moss L, ffrench-Constant C. The neural stem 
cell microenvironment. Cambridge: StemBook; 2008.
4. Joo KM, Kang BG, Yeon JY, Cho YJ, An JY, Song HS, et al. Experi-
mental and clinical factors influencing long-term stable in vitro ex-
pansion of multipotent neural cells from human adult temporal 
lobes. Exp Neurol 2013;240:168-77.
5. Doetsch F. A niche for adult neural stem cells. Curr Opin Genet Dev 
2003;13:543-50.
6. Kallur T, Darsalia V, Lindvall O, Kokaia Z. Human fetal cortical and 
striatal neural stem cells generate region-specific neurons in vitro 
and differentiate extensively to neurons after intrastriatal trans-
plantation in neonatal rats. J Neurosci Res 2006;84:1630-44.
7. Scadden DT. The stem-cell niche as an entity of action. Nature 
2006;441:1075-9.
8. Bokara KK, Kwon KH, Nho Y, Lee WT, Park KA, Lee JE. Retroviral 
expression of arginine decarboxylase attenuates oxidative burden 
in mouse cortical neural stem cells. Stem Cells Dev 2011;20:527-37.
9. Reis DJ, Regunathan S. Is agmatine a novel neurotransmitter in 
brain? Trends Pharmacol Sci 2000;21:187-93.
10. Kim JH, Yenari MA, Giffard RG, Cho SW, Park KA, Lee JE. Agmatine 
reduces infarct area in a mouse model of transient focal cerebral 
ischemia and protects cultured neurons from ischemia-like injury. 
Exp Neurol 2004;189:122-30.
11. Mun CH, Lee WT, Park KA, Lee JE. Regulation of endothelial ni-
tric oxide synthase by agmatine after transient global cerebral isch-
emia in rat brain. Anat Cell Biol 2010;43:230-40.
12. Song HW, Kumar BK, Kim SH, Jeon YH, Lee YA, Lee WT, et al. Ag-
matine enhances neurogenesis by increasing ERK1/2 expression, 
and suppresses astrogenesis by decreasing BMP 2,4 and SMAD 1,5,8 
expression in subventricular zone neural stem cells. Life Sci 2011; 
89:439-49.
13. Navarro A, Monzo M. MicroRNAs in human embryonic and can-
cer stem cells. Yonsei Med J 2010;51:622-32. 
14. Cheng LC, Pastrana E, Tavazoie M, Doetsch F. miR-124 regulates 
adult neurogenesis in the subventricular zone stem cell niche. Nat 
Neurosci 2009;12:399-408.
15. Roush S, Slack FJ. The let-7 family of microRNAs. Trends Cell Biol 
2008;18:505-16.
16. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, 
Maller B, et al. Conservation of the sequence and temporal expres-
sion of let-7 heterochronic regulatory RNA. Nature 2000;408:86-9.
17. Zhao C, Sun G, Li S, Lang MF, Yang S, Li W, et al. MicroRNA let-7b 
regulates neural stem cell proliferation and differentiation by tar-
geting nuclear receptor TLX signaling. Proc Natl Acad Sci U S A 2010; 
107:1876-81.
18. Cimadamore F, Amador-Arjona A, Chen C, Huang CT, Terskikh 
AV. SOX2-LIN28/let-7 pathway regulates proliferation and neuro-
genesis in neural precursors. Proc Natl Acad Sci U S A 2013;110: 
E3017-26. 
19. Zhao C, Sun G, Ye P, Li S, Shi Y. MicroRNA let-7d regulates the TLX/ 
microRNA-9 cascade to control neural cell fate and neurogenesis. 
Sci Rep 2013;3:1329.
20. Wu YC, Chen CH, Mercer A, Sokol NS. Let-7-complex microRNAs 
regulate the temporal identity of Drosophila mushroom body neu-
rons via chinmo. Dev Cell 2012;23:202-9.
21. Kucherenko MM, Barth J, Fiala A, Shcherbata HR. Steroid-induced 
microRNA let-7 acts as a spatio-temporal code for neuronal cell 
fate in the developing Drosophila brain. EMBO J 2012;31:4511-23. 
22. Schwamborn JC, Berezikov E, Knoblich JA. The TRIM-NHL protein 
TRIM32 activates microRNAs and prevents self-renewal in mouse 
neural progenitors. Cell 2009;136:913-25.
23. Loedige I, Filipowicz W. TRIM-NHL proteins take on miRNA reg-
ulation. Cell 2009;136:818-20.
24. Hong S, Son MR, Yun K, Lee WT, Park KA, Lee JE. Retroviral expres-
sion of human arginine decarboxylase reduces oxidative stress in-
jury in mouse cortical astrocytes. BMC Neurosci 2014;15:99.
25. Halaris A, Plietz J. Agmatine : metabolic pathway and spectrum of 
activity in brain. CNS Drugs 2007;21:885-900.
26. Yang XC, Reis DJ. Agmatine selectively blocks the N-methyl-D-as-
partate subclass of glutamate receptor channels in rat hippocam-
pal neurons. J Pharmacol Exp Ther 1999;288:544-9.
27. Iannone L, Zhao L, Dubois O, Duluc L, Rhodes CJ, Wharton J, et al. 
miR-21/DDAH1 pathway regulates pulmonary vascular responses 
to hypoxia. Biochem J 2014;462:103-12.
28. Mullen RJ, Buck CR, Smith AM. NeuN, a neuronal specific nuclear 
protein in vertebrates. Development 1992;116:201-11.
29. Fu X, Brown KJ, Yap CC, Winckler B, Jaiswal JK, Liu JS. Doublecor-
tin (Dcx) family proteins regulate filamentous actin structure in de-
1467
Juhyun Song, et al.
http://dx.doi.org/10.3349/ymj.2016.57.6.1461
veloping neurons. J Neurosci 2013;33:709-21. 
30. Shi Y, Sun G, Zhao C, Stewart R. Neural stem cell self-renewal. Crit 
Rev Oncol Hematol 2008;65:43-53.
31. Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, et al. c-Myc 
is required for maintenance of glioma cancer stem cells. PLoS One 
2008;3:e3769.
32. Tocharus C, Puriboriboon Y, Junmanee T, Tocharus J, Ekthuwapra-
nee K, Govitrapong P. Melatonin enhances adult rat hippocampal 
progenitor cell proliferation via ERK signaling pathway through 
melatonin receptor. Neuroscience 2014;275:314-21.
33. Connor B, Gordon RJ, Jones KS, Maucksch C. Deviating from the 
well travelled path: precursor cell migration in the pathological 
adult mammalian brain. J Cell Biochem 2011;112:1467-74. 
34. El-Agamy DS, Makled MN, Gamil NM. Protective effects of agma-
tine against D-galactosamine and lipopolysaccharide-induced 
fulminant hepatic failure in mice. Inflammopharmacology 2014; 
22:187-94.
35. Park YM, Han SH, Seo SK, Park KA, Lee WT, Lee JE. Restorative 
benefits of transplanting human mesenchymal stromal cells over-
expressing arginine decarboxylase genes after spinal cord injury. 
Cytotherapy 2015;17:25-37.
36. Couillard-Despres S, Winner B, Schaubeck S, Aigner R, Vroemen 
M, Weidner N, et al. Doublecortin expression levels in adult brain 
reflect neurogenesis. Eur J Neurosci 2005;21:1-14.
37. Liu HK, Belz T, Bock D, Takacs A, Wu H, Lichter P, et al. The nuclear 
receptor tailless is required for neurogenesis in the adult subven-
tricular zone. Genes Dev 2008;22:2473-8.
38. Wang T, Ren X, Xiong J, Zhang L, Qu J, Xu W. Tailless-like (TLX) 
protein promotes neuronal differentiation of dermal multipotent 
stem cells and benefits spinal cord injury in rats. Cell Mol Neuro-
biol 2011;31:479-87.
39. Kerosuo L, Piltti K, Fox H, Angers-Loustau A, Häyry V, Eilers M, et 
al. Myc increases self-renewal in neural progenitor cells through 
Miz-1. J Cell Sci 2008;121(Pt 23):3941-50.
40. Koscianska E, Baev V, Skreka K, Oikonomaki K, Rusinov V, Tabler 
M, et al. Prediction and preliminary validation of oncogene regu-
lation by miRNAs. BMC Mol Biol 2007;8:79.
41. Li Y, Liu H, Lai C, Du X, Su Z, Gao S. The Lin28/let-7a/c-Myc path-
way plays a role in non-muscle invasive bladder cancer. Cell Tis-
sue Res 2013;354:533-41.
